Jasper Therapeutics Inc [JSPR] stock is trading at $5.53, down -0.90%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The JSPR shares have lost -0.54% over the last week, with a monthly amount drifted -8.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jasper Therapeutics Inc [NASDAQ: JSPR] stock has seen the most recent analyst activity on February 13, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $38. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $63. On September 09, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $70 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $90 on July 08, 2024. Stifel initiated its recommendation with a Buy and recommended $86 as its price target on June 27, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on May 06, 2024, and assigned it a price target of $65. In a note dated April 03, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $65 on this stock.
Jasper Therapeutics Inc [JSPR] stock has fluctuated between $4.55 and $31.01 over the past year. Currently, Wall Street analysts expect the stock to reach $55.5 within the next 12 months. Jasper Therapeutics Inc [NASDAQ: JSPR] shares were valued at $5.53 at the most recent close of the market. An investor can expect a potential return of 903.62% based on the average JSPR price forecast.
Analyzing the JSPR fundamentals
An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.11 points at the first support level, and at 4.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.78, and for the 2nd resistance point, it is at 6.02.
Ratios To Look Out For
For context, Jasper Therapeutics Inc’s Current Ratio is 4.98. In addition, the Quick Ratio stands at 4.98 and the Cash Ratio stands at 4.7.
Transactions by insiders
Recent insider trading involved Mahal Jeetinder Singh, Chief Operating Officer, that happened on Dec 12 ’24 when 900.0 shares were sold. Executive Officer, Jeetinder Singh Mahal completed a deal on Dec 12 ’24 to buy 900.0 shares. Meanwhile, Chief Operating Officer Mahal Jeetinder Singh sold 900.0 shares on Sep 12 ’24.
